Trial · NCT07803068
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in Maximal strength of upper lower limbs at 12 weeks. | Baseline and 12 weeks. | One-repetition maximum (1RM) in the bench press will be assessed using three attempts with progressively increased loads. Units: kilograms (kg) |
| Primary | Change from Baseline in cortisol levels at 12 weeks | Baseline to 12 weeks | Serum levels of cortisol will be determined using enzyme-linked immunosorbent assay (ELISA) per the manufacturer's instructions. Units: nmol/l |
| Primary | Change from Baseline in BDNF levels at 12 weeks | Baseline to 12 weeks | Serum levels of BDNF will be determined using enzyme-linked immunosorbent assay (ELISA) per the manufacturer's instructions. Units: pg/ml |
| Secondary | Change from Baseline in oxidative stress markers at 12 weeks. | Baseline to 12 weeks. | Spectrophotometric determination of lipid and protein peroxidation products in plasma will be conducted as markers of oxidative damage. |
| Secondary | Change from Baseline in visuospatial memory at 12 weeks | Baseline to 12 weeks | Participants will undergo neuropsychological Visual Patterns Test (VPT) administered by a licensed psychologist to evaluate visuospatial memory. Score will be evaluated as a total score of correctly remembered patterns. |
| Secondary | Change from Baseline in information processing efficiency at 12 weeks | Baseline to 12 weeks | Participants will undergo neuropsychological tests (Trail Making Test Part A and Trail Making Test Part B) administered by a licensed psychologist to evaluate information processing efficiency. Scores will be evaluated as completion time and number of mistakes. Shorter time and less mistakes mean better results. |
| Secondary | Change from Baseline in muscular endurance of upper limbs at 12 weeks. | Baseline and 12 weeks | Maximum number of repetitions at 75% 1RM in the bench press until failure will be performed. Units: number of repetitions |
| Secondary | Change from Baseline in testostrone levels at 12 weeks | Baseline to 12 weeks | Serum levels of testosterone will be determined using enzyme-linked immunosorbent assay (ELISA) per the manufacturer's instructions. Units: nmol/l |
| Secondary | Change from Baseline in subjective sleep quality at 12 weeks. | Baseline and 12 weeks | Participants will fill in a questionnaire Pittsburgh Sleep Quality Index (PSQI). Total scores will be shown on a scale from 0 to 21, with higher scores indicating worse outcomes. |
| Secondary | Change from Baseline in perceived stress at 12 weeks. | Baseline and 12 weeks. | Participants will fill in a questionnaire Perceived Stress Scale (PSS). Total scores will be shown on a scale from 0 to 40, with higher scores indicating worse outcomes. |
| Secondary | Change from Baseline in mood states at 12 weeks. | Baseline and 12 weeks. | Participants will fill in a questionnaire Profile of Mood States (POMS). Total scores will be shown on a Total Mood Disturbance scale from -30 to 200, with higher scores indicating worse outcomes. |
| Secondary | Change from Baseline in Maximal strength of lower limbs at 12 weeks. | Baseline and 12 weeks. | Strength will be assesed using the Biodex (Biodex System 4 Pro, NY, USA) with isometric knee extension at 60 degrees of knee extension and knee flexion at 120 degrees of knee extension. |
| Secondary | Change from Baseline in working memory and information processing efficiency at 12 weeks | Baseline to 12 weeks | Participants will undergo neuropsychological Stroop Test administered by a licensed psychologist to evaluate working memory and information processing efficiency. Scores will be evaluated as completion time and number of mistakes. Shorter time and less mistakes mean better results. |
| Secondary | Change from Baseline in body fat percentage at 12 weeks. | Baseline and 12 weeks | Body fat percentage will be measured using the Seca mBCA 555 bioimpedance analyzer, which estimates the proportion of fat mass relative to total body weight. Units: percentage (%) |
| Secondary | Change from Baseline in lean body mass at 12 weeks. | Baseline and 12 weeks | Lean body mass will be measured using the SECA bioimpedance analyzer, which estimates the proportion of lean body mass to total body weight. Units: kilograms (kg) |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07803068/registered